Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
While chronic exposure to GLP-1Ra appears to be essentially neutral on both systolic and diastolic function, irrespective of left ventricular ejection fraction (LVEF), a beneficial impact of SGLT-2i is consistently detectable for both systolic and diastolic function parameters in subjects with diabetes with and without HF, with a gradient proportional to the severity of baseline dysfunction
It is a research-only package containing five lyophilized vials labelled 5mg per vial
The global market for GLP-1 receptor agonists was valued at USD 53.46 billion in 2024 and is expected to grow to USD 156.71 billion by 2030 , reflecting a compound annual growth rate of 17.46% between 2025 and 2030
patents will have lapsed in countries representing nearly half the global obesity burden by year-end
US$ 27.16
US$ 21.90
US$ 21.69
US$ 29.42
US$ 22.41
